|
Hyperalgesia
|
0.520 |
Biomarker
|
phenotype |
BEFREE |
Selective for COX-2 over COX-1, compound 10 exhibited IC<sub>50</sub> 0.02 µM for COX-2 and reversed acetic acid induced inflammation in rats by 73% when used at 10 mg kg<sup>-1</sup> dose and the same dose of the compound also rescued the animals from inflammatory phase of formalin induced hyperalgesia.
|
31843462 |
2020 |
|
Hyperalgesia
|
0.520 |
GeneticVariation
|
phenotype |
BEFREE |
The prevention of this hyperalgesia by diclofenac (1-10μg), the inhibitors of COX-1 SC-560 (0.1-1μg) or COX-2 celecoxib (1-5μg), the TRPV1 antagonist capsazepine (0.03-0.3μg) or the TRPA1 antagonist HC030031 (10-50μg) demonstrates the involvement of prostaglandin synthesis and TRP sensitization in CCL5-evoked hyperalgesia.
|
28126501 |
2017 |
|
Hyperalgesia
|
0.520 |
Biomarker
|
phenotype |
CTD_human |
The results of the study suggest participation of COX-1, COX-2 and iNOS, but not nNOS, in transmission of pain stimuli in STZ-induced diabetic hyperalgesia.
|
17989504 |
2008 |
|
Hyperalgesia
|
0.520 |
Biomarker
|
phenotype |
RGD |
Spinal prostaglandins facilitate exaggerated A- and C-fiber-mediated reflex responses and are critical to the development of allodynia early after L5-L6 spinal nerve ligation.
|
17413918 |
2007 |
|
Malignant neoplasm of breast
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
The F-derivative of the -SOMe substituted furan-3(<i>2H</i>)-ones exhibited the best activity (COX-1 IC<sub>50</sub> = 2.8 μM, anti-inflammatory activity (by carrageenan paw edema model) of 54% (dose 0.01 mmol/kg), and MCF-7 and HSC-3 cytotoxicity with IC<sub>50</sub> values of 10 μM and 7.5 μM, respectively).
|
31064095 |
2019 |
|
Breast Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
The F-derivative of the -SOMe substituted furan-3(<i>2H</i>)-ones exhibited the best activity (COX-1 IC<sub>50</sub> = 2.8 μM, anti-inflammatory activity (by carrageenan paw edema model) of 54% (dose 0.01 mmol/kg), and MCF-7 and HSC-3 cytotoxicity with IC<sub>50</sub> values of 10 μM and 7.5 μM, respectively).
|
31064095 |
2019 |
|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
In cellular systems, with exception of the 6-Cl derivative, all compounds showed notable antitumor activity in COX-1/2 expressing tumor cells (HT-29 (IC<sub>50</sub> = 1.5-2.7 μM), MDA-MB-231 (IC<sub>50</sub> = 5.2-8.0 μM)), but were distinctly less active in the COX-1/2-negative MCF-7 breast cancer cell line (IC<sub>50</sub> = 15.2-22.9 μM).
|
29492489 |
2018 |
|
Breast Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
In cellular systems, with exception of the 6-Cl derivative, all compounds showed notable antitumor activity in COX-1/2 expressing tumor cells (HT-29 (IC<sub>50</sub> = 1.5-2.7 μM), MDA-MB-231 (IC<sub>50</sub> = 5.2-8.0 μM)), but were distinctly less active in the COX-1/2-negative MCF-7 breast cancer cell line (IC<sub>50</sub> = 15.2-22.9 μM).
|
29492489 |
2018 |
|
Malignant neoplasm of breast
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.
|
19276290 |
2009 |
|
Breast Carcinoma
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.
|
19276290 |
2009 |
|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
CTD_human |
Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo.
|
18488158 |
2008 |
|
Breast Carcinoma
|
0.360 |
Biomarker
|
disease |
CTD_human |
Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo.
|
18488158 |
2008 |
|
Malignant neoplasm of breast
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
The prostaglandin PGE(2) increases intracellular cAMP levels and stimulates estrogen biosynthesis, and our recent studies have shown a strong linear association between CYP19 expression and the sum of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) expression in breast cancer specimens.
|
11897504 |
2002 |
|
Breast Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
The prostaglandin PGE(2) increases intracellular cAMP levels and stimulates estrogen biosynthesis, and our recent studies have shown a strong linear association between CYP19 expression and the sum of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) expression in breast cancer specimens.
|
11897504 |
2002 |
|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
Human breast cancer cell line Hs578T was stably transfected with cDNA for cyclooxygenase-1 or -2.
|
10571077 |
1999 |
|
Breast Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
Human breast cancer cell line Hs578T was stably transfected with cDNA for cyclooxygenase-1 or -2.
|
10571077 |
1999 |
|
Malignant neoplasm of breast
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Surgical specimens from 44 patients with breast cancer who had undergone lumpectomy or mastectomy were analyzed by immunoblot analysis and immunohistochemical analysis to determine the expression profile of the constitutively expressed form of cyclooxygenase (COX-1) and the inducible form (COX-2); the specimens from 14 patients included normal breast tissue.
|
9521170 |
1998 |
|
Breast Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Surgical specimens from 44 patients with breast cancer who had undergone lumpectomy or mastectomy were analyzed by immunoblot analysis and immunohistochemical analysis to determine the expression profile of the constitutively expressed form of cyclooxygenase (COX-1) and the inducible form (COX-2); the specimens from 14 patients included normal breast tissue.
|
9521170 |
1998 |
|
Carcinoma
|
0.350 |
AlteredExpression
|
group |
BEFREE |
Expression of COX-1 mRNA in the normal thyroid tissues, follicular adenomas and both well-differentiated carcinomas was similar and weak.
|
16362262 |
2006 |
|
Carcinoma
|
0.350 |
Biomarker
|
group |
BEFREE |
This study was designed to investigate the expression and molecular signaling of cyclooxygenase-1 (COX-1) in cervical carcinomas.
|
11809691 |
2002 |
|
Carcinoma
|
0.350 |
Biomarker
|
group |
CTD_human |
Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol.
|
12189197 |
2002 |
|
Carcinoma
|
0.350 |
AlteredExpression
|
group |
BEFREE |
Expression of cyclooxygenase-1 and -2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells.
|
11827414 |
2001 |
|
Carcinoma
|
0.350 |
Biomarker
|
group |
BEFREE |
Paraffin embedded tissues from 75 patients with urothelial carcinomas were immunostained with specific antibodies raised against COX-1 and COX-2.
|
10880372 |
2000 |
|
Carcinoma
|
0.350 |
AlteredExpression
|
group |
BEFREE |
Two Cox genes have been cloned (Cox-1 and Cox-2), of which Cox-2 has recently been found to be expressed in several human carcinomas.
|
9823297 |
1998 |
|
Gastric ulcer
|
0.340 |
Biomarker
|
disease |
BEFREE |
The inhibition of gastric cyclooxygenase 1 (COX-1) enzyme was believed to be the major cause of non-steroidal anti-inflammatory drugs (NSAIDs)-induced gastric ulcer.
|
27916468 |
2017 |